Premium
Treatment of advanced myelodysplastic syndrome with a regimen including recombinant human granulocyte colony‐stimulating factor preceding allogeneic bone marrow transplantation
Author(s) -
OKAMOTO SHINICHIRO,
TAKAHASHI SATOSHI,
WAKUI MASATOSHI,
ISHIDA AKARU,
TANOSAKI RYUJI,
IKEDA YASUO,
ASANO SHIGETAKA
Publication year - 1999
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1046/j.1365-2141.1999.01205.x
Subject(s) - granulocyte colony stimulating factor , regimen , medicine , myelodysplastic syndromes , transplantation , bone marrow , granulocyte , cytarabine , total body irradiation , chemotherapy , surgery , immunology , gastroenterology , oncology , cyclophosphamide
We treated 13 patients with morphologically advanced myelodysplastic syndrome using cytosine arabinoside and total body irradiation, followed by allogeneic marrow transplantation from HLA‐identical sibling donors. Granulocyte colony‐stimulating factor (G‐CSF) was added to the preparative regimen to selectively increase chemosensitivity of leukaemic cells and to improve transplant outcome. No regimen‐related deaths occurred, and no side‐effects related to the addition of G‐CSF were observed except for transient mild bone pain. At a median follow‐up time of 39 months the projected 5‐year disease‐free survival and 5‐year overall survival were 67.7% and 75.5%, respectively, with only one case showing cytogenetic relapse. The preparative regimen including G‐CSF is feasible, and preliminary results seem to be encouraging. However, a larger trial is clearly warranted to evaluate its efficacy.